Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693–705 (2007).
  Medline CASGoogle Scholar
• 2 Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338(1), 17–31 (2004).
  Medline CASGoogle Scholar
• 3 Baylin SB, Ohm JE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6(2), 107–116 (2006).
  Medline CASGoogle Scholar
• 4 Kalveram B, Schmidtke G, Groettrup M. The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J. Cell. Sci. 121(Pt 24), 4079–4088 (2008).
  Medline CASGoogle Scholar
• 5 Kovacs JJ, Murphy PJ, Gaillard S et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell. 18(5), 601–607 (2005).
  Medline CASGoogle Scholar
• 6 Parmigiani RB, Xu WS, Venta-Perez G et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl Acad. Sci. USA 105(28), 9633–9638 (2008).
  Medline CASGoogle Scholar
• 7 Zhang X, Yuan Z, Zhang Y et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol. Cell 27(2), 197–213 (2007).
  Medline CASGoogle Scholar
• 8 Hubbert C, Guardiola A, Shao R et al. HDAC6 is a microtubule-associated deacetylase. Nature 417(6887), 455–458 (2002). •• Reports the role of HDAC6 enzyme as a tubulin deacetylase and provides evidence that reversible acetylation regulates important biological processes beyond histone metabolism and gene transcription.
  Medline CASGoogle Scholar
• 9 Lee JH, Mahendran A, Yao Y et al. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc. Natl Acad. Sci. USA 110(39), 15704–15709 (2013).
  Medline CASGoogle Scholar
• 10 Kramer OH, Mahboobi S, Sellmer A. Drugging the HDAC6-HSP90 interplay in malignant cells. Trends Pharmacol. Sci. 35(10), 501–509 (2014). • Describes the complexity and the importance of the HDAC6-Hsp90 interplay and its role in controlling oncologically relevant pathways.
  MedlineGoogle Scholar
• 11 Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr. Cancer Drug Targets 9(6), 761–776 (2009).
  Medline CASGoogle Scholar
• 12 Kawaguchi Y, Kovacs JJ, Mclaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6), 727–738 (2003). •• Reports the identification of HDAC6 as a crucial player in the cellular management of misfolded protein-induced stress, demonstrating that HDAC6 has the capacity to bind both polyubiquitinated misfolded proteins and dynein motors.
  Medline CASGoogle Scholar
• 13 Boyault C, Zhang Y, Fritah S et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 21(17), 2172–2181 (2007).
  Medline CASGoogle Scholar
• 14 Kwon S, Zhang Y, Matthias P. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev. 21(24), 3381–3394 (2007).
  Medline CASGoogle Scholar
• 15 Bradbury CA, Khanim FL, Hayden R et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19(10), 1751–1759 (2005).
  Medline CASGoogle Scholar
• 16 Van Damme M, Crompot E, Meuleman N et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 7(12), 1403–1412 (2012).
  Medline CASGoogle Scholar
• 17 Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 53(3), 267–277 (2008).
  Medline CASGoogle Scholar
• 18 Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 280(3), 775–793 (2013).
  Medline CASGoogle Scholar
• 19 Dallavalle S, Pisano C, Zunino F. Development and therapeutic impact of HDAC6-selective inhibitors. Biochem. Pharmacol. 84(6), 756–765 (2012).
  Medline CASGoogle Scholar
• 20 Muller S, Kramer OH. Inhibitors of HDACs-effective drugs against cancer? Curr. Cancer Drug Targets 10(2), 210–228 (2010).
  Medline CASGoogle Scholar
• 21 Mair B, Kubicek S, Nijman SM. Exploiting epigenetic vulnerabilities for cancer therapeutics. Trends Pharmacol. Sci. 35(3), 136–145 (2014).
  Medline CASGoogle Scholar
• 22 Rambaldi A, Dellacasa CM, Finazzi G et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br. J. Haematol. 150(4), 446–455 (2010).
  Medline CASGoogle Scholar
• 23 Sholler GS, Currier EA, Dutta A et al. PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. J. Cancer Ther. Res. 2 21 (2013).
  MedlineGoogle Scholar
• 24 Butini S, Gabellieri E, Brindisi M et al. A stereoselective approach to peptidomimetic BACE1 inhibitors. Eur. J. Med. Chem. 70 233–247 (2013).
  Medline CASGoogle Scholar
• 25 Butini S, Gemma S, Brindisi M et al. Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies. J. Med. Chem. 54(5), 1401–1420 (2011).
  Medline CASGoogle Scholar
• 26 Savi L, Brindisi M, Alfano G et al. Site-directed mutagenesis of key residues unveiled a novel allosteric site on human adenosine kinase for Pyrrolobenzoxa(thia)zepinone non-nucleoside inhibitors. Chem. Biol. Drug Des. 87(1), 112–120 (2016).
  Medline CASGoogle Scholar
• 27 Giovani S, Penzo M, Brogi S et al. Rational design of the first difluorostatone-based PfSUB1 inhibitors. Bioorg. Med. Chem. Lett. 24(15), 3582–3586 (2014).
  Medline CASGoogle Scholar
• 28 Butini S, Guarino E, Campiani G et al. Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. Bioorg. Med. Chem. Lett. 18(19), 5213–5216 (2008).
  Medline CASGoogle Scholar
• 29 Ghosh AK, Brindisi M, Yen YC et al. Structure-based design, synthesis and biological evaluation of novel beta-secretase inhibitors containing a pyrazole or thiazole moiety as the P3 ligand. Bioorg. Med. Chem. Lett. 25(3), 668–672 (2015).
  Medline CASGoogle Scholar
• 30 Brindisi M, Brogi S, Relitti N et al. Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking. Sci. Rep. 5, 9705 (2015).
  Medline CASGoogle Scholar
• 31 Giovani S, Penzo M, Butini S et al. Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors. RSC Adv. 5(29), 22431–22448 (2015).
  CASGoogle Scholar
• 32 Brogi S, Giovani S, Brindisi M et al. In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors. J. Mol. Graph. Model. 64, 121–130 (2016).
  Medline CASGoogle Scholar
• 33 Butini S, Brindisi M, Gemma S et al. Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases. J. Med. Chem. 55(15), 6898–6915 (2012).
  Medline CASGoogle Scholar
• 34 Butini S, Gemma S, Brindisi M et al. Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties. Bioorg. Med. Chem. Lett. 23(2), 492–495 (2013).
  Medline CASGoogle Scholar
• 35 Heltweg B, Trapp J, Jung M. In vitro assays for the determination of histone deacetylase activity. Methods 36(4), 332–337 (2005).
  Medline CASGoogle Scholar
• 36 Heltweg B, Dequiedt F, Verdin E, Jung M. Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal. Biochem. 319(1), 42–48 (2003).
  Medline CASGoogle Scholar
• 37 Wegener D, Wirsching F, Riester D, Schwienhorst A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 10(1), 61–68 (2003).
  Medline CASGoogle Scholar
• 38 Miles KC, Mays SM, Southerland BK, Auvil TJ, Ketcha DM. The Clauson-Kass pyrrole synthesis under microwave irradiation. ARKIVOC 2009, 181–190 (2009).
  Google Scholar
• 39 Millard CJ, Watson PJ, Celardo I et al. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol. Cell. 51(1), 57–67 (2013).
  Medline CASGoogle Scholar
• 40 Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132(31), 10842–10846 (2010).
  Medline CASGoogle Scholar
• 41 Kaliszczak M, Trousil S, Aberg O, Perumal M, Nguyen QD, Aboagye EO. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br. J. Cancer 108(2), 342–350 (2013).
  Medline CASGoogle Scholar
• 42 Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5(4), 725–738 (2010).
  Medline CASGoogle Scholar
• 43 Giovani S, Penzo M, Brogi S et al. Rational design of the first difluorostatone-based PfSUB1 inhibitors. Bioorg. Med. Chem. Lett. 24(15), 3582–3586 (2014).
  Medline CASGoogle Scholar
• 44 Gemma S, Brogi S, Patil PR et al. From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum. RSC Adv. 4, 4769–4781 (2014).
  CASGoogle Scholar
• 45 Gasser A, Brogi S, Urayama K et al. Discovery and cardioprotective effects of the first non-peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS ONE 10(4), e0121027 (2015).
  MedlineGoogle Scholar